Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Adds More MDRs, Deaths, To Philips Ventilator Tally

Executive Summary

Less than a month after Philips released test results that it said showed the company’s much scrutinized sleep therapy devices were safe, the FDA has reported more complaints, including deaths, associated with the machines.

You may also be interested in...



In Times Of Adversity, Surgical Robot Developers Must Remain Sharp

Harsh economic conditions and increased competition are dictating that surgical robotics companies must quickly adopt new commercial strategies. In Vivo speaks to key players in the space to learn more.

Vindication, Or Spin? Philips Says Tests Confirm Safety Of Breathing Machines. Plaintiff Attorneys Argue Results Lack Credibility

Royal Philips says independent tests show its sleep therapy devices, which have been the subject of controversy since being recalled in June 2021, are safe and unlikely to harm patients. Attorneys representing patients suing the company call the results a shameless attempt to deflect blame.

News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR

This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147973

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel